ARA-290 (Cibinetide) Peptide: Neuropathy Evidence and Safety Limits
ARA-290 cibinetide guide covering small-fiber neuropathy trials, diabetic neuropathy data, nerve-fiber endpoints, mechanism and peptide-market safety limits.
ARA-290 is getting attention because the claim is more specific than the usual "recovery peptide" pitch. The compound, also called cibinetide, has been studied in people with small-fiber neuropathy, especially sarcoidosis-associated small nerve fiber loss and painful neuropathy in type 2 diabetes.
That makes ARA-290 more evidence-grounded than many research-peptide listings, but it does not make the leap to a consumer nerve-repair protocol. The human studies are small, short and tied to defined populations. They measure symptoms, corneal nerve fiber markers, skin nerve fiber markers and metabolic endpoints, not every kind of nerve injury or chronic pain.
For PeptideStat context, compare this guide with BPC-157, BPC-157 vs TB-500, KPV peptide, thymosin alpha-1, and SS-31 elamipretide. If you are evaluating vial-handling claims, also use peptide storage, peptide reconstitution, and how to inject peptides safely.
This guide is educational and not medical advice. ARA-290/cibinetide is not an approved neuropathy drug. Neuropathic pain, dysautonomia, diabetes, sarcoidosis and immune disease need clinician evaluation, diagnosis-specific treatment and monitoring.
ARA-290 At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | An 11-amino-acid peptide derived from erythropoietin tissue-protective biology. |
| Other name | Cibinetide. |
| Main proposed target | The innate repair receptor, usually discussed as an EPOR/CD131 receptor complex. |
| Strongest human evidence | Small phase 2 studies in sarcoidosis-associated small-fiber neuropathy and type 2 diabetes with painful neuropathy. |
| Main endpoints studied | Neuropathic symptoms, corneal confocal microscopy, skin small-fiber markers, walking function and metabolic markers. |
| FDA status | No FDA-approved cibinetide product label for neuropathy or nerve repair as of this update. |
| Main marketing drift | Broad "nerve regeneration," injury recovery, dysautonomia and pain claims without population-specific proof. |
What ARA-290 Is
ARA-290 was designed from erythropoietin, or EPO, but it is not meant to work like conventional EPO therapy. EPO can stimulate red blood cell production, which is part of why EPO-like drugs carry important hematologic and thrombotic-risk considerations. ARA-290 was engineered as a nonerythropoietic peptide, meaning its development rationale is tissue protection and repair signaling rather than red-cell stimulation.
The common mechanism phrase is "innate repair receptor." Researchers describe cibinetide as acting through an erythropoietin receptor and beta-common receptor complex, often abbreviated EPOR/CD131. That mechanism is interesting because small-fiber neuropathy involves pain, sensory disturbance and autonomic features that can be difficult to treat with standard symptom-control drugs.
Mechanism still does not equal clinical proof. The useful question is whether ARA-290 changed measured outcomes in people, whether those outcomes were clinically meaningful, and whether results were replicated in larger, longer-term studies.
Human Evidence By Population
| Population or model | What was studied | What the evidence supports | What remains limited |
|---|---|---|---|
| Sarcoidosis-associated small-fiber neuropathy | Pilot and phase 2 studies using ARA-290/cibinetide | Symptom changes and corneal nerve-fiber measurements in small studies | Short duration, small samples and specialized population |
| Type 2 diabetes with painful neuropathy | Phase 2 daily subcutaneous ARA-290 over 28 days | PainDetect symptom changes, HbA1c/lipid observations and corneal nerve-fiber measures | Not a pivotal diabetes-neuropathy trial and not an approved diabetes treatment |
| Corneal small nerve fiber loss | Corneal confocal microscopy as a surrogate endpoint | Structural nerve-fiber measures can be tracked in trials | Surrogate changes do not automatically prove durable clinical benefit |
| Diabetic wound models | Mouse studies of impaired wound healing | Preclinical tissue-repair rationale | Animal wound data do not establish human wound or recovery use |
| General nerve injury or dysautonomia | Forum discussion and mechanistic extrapolation | Real search demand and hypothesis generation | No direct proof for broad consumer claims |
Sarcoidosis Small-Fiber Neuropathy Data
Sarcoidosis-associated small-fiber neuropathy is the most important clinical context for ARA-290. Sarcoidosis can involve immune inflammation, pain, temperature-sensation problems and autonomic symptoms. Small-fiber neuropathy in this setting is not the same problem as a sports injury, sciatica or general "nerve damage."
The randomized pilot study tested intravenous ARA-290 in sarcoidosis patients with small-fiber neuropathy symptoms. It was small and early, but it gave the field a controlled human signal rather than only animal data.
A later open-label sarcoidosis study reported symptom improvement and increased corneal nerve fiber density. The phase 2b study then used corneal confocal microscopy and skin small-fiber markers in a 28-day randomized design. PubMed lists that study as a randomized controlled trial and reports cibinetide doses of 1, 4 or 8 mg daily compared with placebo.
Those details matter for two reasons. First, ARA-290 is not evidence-free. Second, the evidence is not a general endorsement. A 28-day trial in sarcoidosis-associated small nerve fiber loss cannot answer whether a research vial helps every neuropathy diagnosis, every autonomic condition or every injury recovery claim.
Type 2 Diabetes And Painful Neuropathy
ARA-290 also has a phase 2 study in people with type 2 diabetes and painful neuropathy. Participants self-administered 4 mg ARA-290 or placebo daily for 28 days, then were followed for an additional month.
The PubMed abstract reports improvements in PainDetect neuropathic symptom scores in the ARA-290 group and observations around HbA1c, lipid profiles and corneal nerve fiber density in a subgroup with reduced baseline corneal nerve fiber density. That is a meaningful clinical research signal.
It is also easy to overread. A 28-day phase 2 study is not a replacement for a large diabetes-neuropathy program with durable pain, nerve-function, safety and metabolic outcomes. The metabolic observations should be read as exploratory unless larger controlled studies reproduce them.
Why Corneal Nerve Fibers Appear In The Studies
Corneal confocal microscopy shows up repeatedly in ARA-290 research because the cornea has small nerve fibers that can be imaged noninvasively. In small-fiber neuropathy research, corneal nerve fiber density or area can serve as a structural biomarker.
That is useful because neuropathy symptoms can be subjective and variable. Structural markers can add a second layer. The limitation is that a biomarker change does not automatically mean durable functional recovery, lower long-term pain burden or reversal of the underlying disease.
The careful reading is narrow: human evidence indicates ARA-290 has been studied with symptom and small nerve fiber endpoints. It does not establish a broad "nerve regrowth peptide" claim.
Safety And Evidence Limits
The published small studies generally did not identify major short-term safety signals in their specific designs. That is not the same as long-term safety in unselected consumers.
The safety gaps are practical:
- Trial samples were small.
- Treatment windows were short.
- Studied participants had defined diseases.
- Product quality was controlled in research settings.
- Research-market vials do not carry an FDA-reviewed label, manufacturing controls, sterility assurance or adverse-event reporting system.
Neuropathy can come from diabetes, autoimmune disease, sarcoidosis, chemotherapy, vitamin deficiency, thyroid disease, infections, medications, toxins and many other causes. A peptide-store protocol that skips diagnosis is not evidence-based care.
How To Evaluate ARA-290 Claims
| Claim | Better question |
|---|---|
| "Repairs nerves" | Which nerve endpoint was measured, in which disease, and for how long? |
| "Works for neuropathy" | Was the condition sarcoidosis-associated small-fiber neuropathy, diabetic neuropathy or something else? |
| "Regenerates corneal nerves" | Was this corneal confocal microscopy in a controlled trial or a marketing statement? |
| "Same as the clinical study product" | Is it a regulated investigational product or an online research vial? |
| "No EPO risks" | Does the source distinguish nonerythropoietic design from complete long-term safety proof? |
Reddit and small-fiber-neuropathy forums show why the topic gets searched: people are looking for options when pain, burning, dysautonomia and sensory symptoms persist. Those discussions are useful for identifying questions, not for proving benefit or setting a protocol.
Where ARA-290 Fits
ARA-290 sits in a stronger evidence tier than many recovery peptides because it has controlled human trials and defined surrogate endpoints. It is more clinical than broad claims around BPC-157 or TB-500, where human outcome evidence is much thinner.
It still belongs below approved medications and diagnosis-specific care. Cibinetide has not become an FDA-approved neuropathy drug. The published studies are best read as investigational signals in small-fiber neuropathy research, not as proof of consumer use.
If your main question is general peptide biology, start with what peptides are. If your question is peptide math or handling, use peptide half-life explained and the peptide calculators. Those tools do not turn investigational evidence into medical instructions.
Bottom Line
ARA-290, or cibinetide, is a real investigational peptide with human small-fiber neuropathy research behind it. The strongest evidence involves sarcoidosis and type 2 diabetes populations, with short phase 2 studies measuring symptoms and small nerve fiber endpoints.
The honest conclusion is narrow. ARA-290 has been studied for small-fiber neuropathy signals, including corneal nerve fiber measures. It is not an approved nerve-repair drug, not a general recovery peptide, and not a substitute for diagnosing and treating the cause of neuropathy.
References
Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Heij L, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
Brines M, et al. Targeting the innate repair receptor to treat neuropathy.
Hoitsma E, et al. Sarcoidosis and small-fiber neuropathy.
Hamed S, et al. Activation of the EPOR-beta common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.